The efficacy of atomoxetine (Strattera/Eli Lilly) for attention-deficit/hyperactivity disorder (ADHD) has been demonstrated in patients with and without comorbid psychiatric conditions, and a new review suggests that the treatment does not adversely affect those conditions. Although the reviewers found that up to 52% of children and adolescents and 87% of adults with ADHD are estimated to have other psychiatric conditions, they found no review of how those conditions may impact the therapeutic effect of atomoxetine on ADHD, or are affected by the treatment.